Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2013

Open Access 01-12-2013 | Research

Impact of chronic diuretic treatment on glucose homeostasis

Authors: Silvio Buscemi, Antonio Nicolucci, Giuseppe Lucisano, Fabio Galvano, Giuseppe Grosso, Fatima M Massenti, Emanuele Amodio, Alice Bonura, Delia Sprini, Giovam B Rini

Published in: Diabetology & Metabolic Syndrome | Issue 1/2013

Login to get access

Abstract

Background

The use of diuretics for hypertension has been associated with unfavorable changes in cardiovascular risk factors, such as uric acid and glucose tolerance, though the findings in the literature are contradictory.

Methods

This study investigated whether diuretic use is associated with markers of metabolic and cardiovascular risk, such as insulin-resistance and uric acid, in a cohort of adults without known diabetes and/or atherosclerotic cardiovascular disease. Nine hundred sixty-nine randomly selected participants answered a questionnaire on clinical history and dietary habits. Laboratory blood measurements were obtained in 507 participants.

Results

Previously undiagnosed type 2 diabetes was recognized in 4.2% of participants who were on diuretics (n = 71), and in 2% of those who were not (n = 890; P = 0.53). Pre-diabetes was diagnosed in 38% of patients who were on diuretics, and in 17.4% (P < 0.001) of those who were not. Multivariate analysis showed that insulin-resistance (HOMA-IR) was associated with the use of diuretics (P = 0.002) independent of other well-known predisposing factors, such as diet, physical activity, body mass index, and waist circumference. The use of diuretics was also independently associated with fasting plasma glucose concentrations (P = 0.001) and uric acid concentrations (P = 0.01).

Conclusions

The use of diuretics is associated with insulin-resistance and serum uric acid levels and may contribute to abnormal glucose tolerance.
Literature
1.
go back to reference National Institute of Health: National Institute of Diabetes and Digestive and Kidney Diseases: Diabetes in America. 1995, Bethesda, US: National Institute of Health, 2 National Institute of Health: National Institute of Diabetes and Digestive and Kidney Diseases: Diabetes in America. 1995, Bethesda, US: National Institute of Health, 2
2.
3.
go back to reference Aromaa A, Reunanen A, Pyorala K: Hypertension and mortality in diabetic and non-dibetic Finnish men. J Hypertens. 1984, 2: 205-207. Aromaa A, Reunanen A, Pyorala K: Hypertension and mortality in diabetic and non-dibetic Finnish men. J Hypertens. 1984, 2: 205-207.
4.
go back to reference Eriksson JW, Jansson PA, Carlberg B, Hagg A, Kurland L, Svensson MK, Ahlstrom H, Strom C, Lonn L, Ojbrandt K, Johansson L, Lind L: Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation. Hypertension. 2008, 52: 1030-1037.CrossRefPubMed Eriksson JW, Jansson PA, Carlberg B, Hagg A, Kurland L, Svensson MK, Ahlstrom H, Strom C, Lonn L, Ojbrandt K, Johansson L, Lind L: Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation. Hypertension. 2008, 52: 1030-1037.CrossRefPubMed
5.
go back to reference Stears AJ, Woods SH, Watts MM, Burton TJ, Graggaber J, Mir FA, Brown MJ: A double-blind, placebo controlled, crossover trial comparing the effects of Amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012, 59: 934-942.CrossRefPubMed Stears AJ, Woods SH, Watts MM, Burton TJ, Graggaber J, Mir FA, Brown MJ: A double-blind, placebo controlled, crossover trial comparing the effects of Amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012, 59: 934-942.CrossRefPubMed
6.
go back to reference Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007, 369: 201-207.CrossRefPubMed Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007, 369: 201-207.CrossRefPubMed
7.
go back to reference Meisinger C, Stockl D, Ruckert IM, Doring A, Thorand B, Heier M, Huth C, Belcredi P, Kowall B, Rathmann W: Serum potassium is associated with prediabetes and newly diagnosed diabetes in hypertensive adults from the general population: the KORA F4-study. Diabetologia. 2013, 56: 484-491.CrossRefPubMed Meisinger C, Stockl D, Ruckert IM, Doring A, Thorand B, Heier M, Huth C, Belcredi P, Kowall B, Rathmann W: Serum potassium is associated with prediabetes and newly diagnosed diabetes in hypertensive adults from the general population: the KORA F4-study. Diabetologia. 2013, 56: 484-491.CrossRefPubMed
8.
go back to reference Lundgren H, Bjorkman L, Keiding P, Lundmark S, Bengtsson C: Diabetes in patients with hypertension receiving pharmacological treatment. BMJ. 1988, 297: 1512-PubMedCentralCrossRefPubMed Lundgren H, Bjorkman L, Keiding P, Lundmark S, Bengtsson C: Diabetes in patients with hypertension receiving pharmacological treatment. BMJ. 1988, 297: 1512-PubMedCentralCrossRefPubMed
9.
go back to reference Bengtsson C, Blohmé C, Lapidus L, Lundgren H: Diabetes in hypertensive women: an effect of antihypertensive drugs or the hypertensive state per se ?. Diabet Med. 1988, 5: 261-264.CrossRefPubMed Bengtsson C, Blohmé C, Lapidus L, Lundgren H: Diabetes in hypertensive women: an effect of antihypertensive drugs or the hypertensive state per se ?. Diabet Med. 1988, 5: 261-264.CrossRefPubMed
10.
go back to reference Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan G, Probstfield JL, Stamler J: Influence of long-term, low dose, diuretic based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Arch Intern Med. 1998, 158: 741-751.CrossRefPubMed Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan G, Probstfield JL, Stamler J: Influence of long-term, low dose, diuretic based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Arch Intern Med. 1998, 158: 741-751.CrossRefPubMed
11.
go back to reference ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288: 2981-2997.CrossRef ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288: 2981-2997.CrossRef
12.
go back to reference McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, Coresh J: Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension. Arthritis Rheum. 2012, 64: 121-129.PubMedCentralCrossRefPubMed McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, Coresh J: Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension. Arthritis Rheum. 2012, 64: 121-129.PubMedCentralCrossRefPubMed
13.
go back to reference Franse LV, Pahorb M, Di Baric M, Shorrd RI, Wand JY, Somesd GW, Applegatee WB: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens. 2000, 18: 1149-1154.CrossRefPubMed Franse LV, Pahorb M, Di Baric M, Shorrd RI, Wand JY, Somesd GW, Applegatee WB: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens. 2000, 18: 1149-1154.CrossRefPubMed
14.
go back to reference Vijan S, Hayward RA: Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003, 138: 593-602.CrossRefPubMed Vijan S, Hayward RA: Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003, 138: 593-602.CrossRefPubMed
15.
go back to reference Gu Q, Burt VL, Dillon CF, Yoon S: Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012, 126: 2105-2114.CrossRefPubMed Gu Q, Burt VL, Dillon CF, Yoon S: Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012, 126: 2105-2114.CrossRefPubMed
16.
go back to reference Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O’Connor CM, O’Gara PT, Oparil S: Treatment of hypertension in the prevention and management of ischemic heart disease - a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007, 115: 2761-2788.CrossRefPubMed Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O’Connor CM, O’Gara PT, Oparil S: Treatment of hypertension in the prevention and management of ischemic heart disease - a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007, 115: 2761-2788.CrossRefPubMed
17.
go back to reference Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al: Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007, 28: 1462-1536.PubMed Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al: Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007, 28: 1462-1536.PubMed
18.
go back to reference Cooper-DeHoff RM, Pacanowski MA, Pepine CJ: Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol. 2009, 53s5: 28-34.CrossRef Cooper-DeHoff RM, Pacanowski MA, Pepine CJ: Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol. 2009, 53s5: 28-34.CrossRef
19.
go back to reference Fujiwara W, Izawa H, Ukai G, Yokoi H, Mukaide D, Kinoshita K, Morimoto SI, Ishii J, Ozaki Y, Nomura M: Low dose hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart Vessels. 2012, PMID: 22447467- Fujiwara W, Izawa H, Ukai G, Yokoi H, Mukaide D, Kinoshita K, Morimoto SI, Ishii J, Ozaki Y, Nomura M: Low dose hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart Vessels. 2012, PMID: 22447467-
20.
go back to reference Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006, 29: 2592-2597.CrossRefPubMed Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006, 29: 2592-2597.CrossRefPubMed
21.
go back to reference Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC: Angiotensin receptor blocker/diurectic combination preserves insulin responses in obese hypertensives. J Hypertens. 2010, 28: 176-179. Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC: Angiotensin receptor blocker/diurectic combination preserves insulin responses in obese hypertensives. J Hypertens. 2010, 28: 176-179.
22.
go back to reference Willett W: Nutrition Epidemiology. 1988, New York: Oxford University Press, 2 Willett W: Nutrition Epidemiology. 1988, New York: Oxford University Press, 2
23.
go back to reference Buscemi S, Nicolucci A, Mattina A, Rosafio G, Massenti FM, Lucisano G, Galvano F, Amodio E, Pellegrini E, Barile AM, Maniaci V, Grosso G, Verga S, Sprini D, Rini GB: Association of dietary patterns with insulin resistance and clinically silent carotid atherosclerosis in apparently healthy people. Eur J Clin Nutr. 2013, 67: 1284-1290.CrossRefPubMed Buscemi S, Nicolucci A, Mattina A, Rosafio G, Massenti FM, Lucisano G, Galvano F, Amodio E, Pellegrini E, Barile AM, Maniaci V, Grosso G, Verga S, Sprini D, Rini GB: Association of dietary patterns with insulin resistance and clinically silent carotid atherosclerosis in apparently healthy people. Eur J Clin Nutr. 2013, 67: 1284-1290.CrossRefPubMed
24.
go back to reference American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013, 36s1: 67-74.CrossRef American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013, 36s1: 67-74.CrossRef
25.
go back to reference Friedewald WT: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed Friedewald WT: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed
26.
go back to reference Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG: Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004, 21: 929-937.CrossRef Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG: Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004, 21: 929-937.CrossRef
27.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419.CrossRefPubMed
28.
go back to reference Salvetti A, Ghiadoni L: Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol. 2006, 17s2: 25-29.CrossRef Salvetti A, Ghiadoni L: Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol. 2006, 17s2: 25-29.CrossRef
29.
go back to reference Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL: Thiazide diuretics, potassium, and the development of diabetes. Hypertension. 2006, 48: 219-224.CrossRefPubMed Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL: Thiazide diuretics, potassium, and the development of diabetes. Hypertension. 2006, 48: 219-224.CrossRefPubMed
30.
go back to reference Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, Travia D, Zenti MG, Branzi P, Santi L, Muggeo M: Relationship of uric acid concentration to cardiovascular risk factors in young men. The role of obesity and central fat distribution. The Verona young Men atherosclerosis risk factors study. Int J Obes Relat Metab Disord. 1996, 20: 975-980.PubMed Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, Travia D, Zenti MG, Branzi P, Santi L, Muggeo M: Relationship of uric acid concentration to cardiovascular risk factors in young men. The role of obesity and central fat distribution. The Verona young Men atherosclerosis risk factors study. Int J Obes Relat Metab Disord. 1996, 20: 975-980.PubMed
31.
go back to reference Zavaroni I, Mazza S, Fantuzzi M, Dall’Aglio E, Bonora E, Delsignore R, Passeri M, Reaven GM: Changes in insulin and lipid metabolism in males with asymptomatic hyperuricemia. J Intern Med. 1993, 234: 25-30.CrossRefPubMed Zavaroni I, Mazza S, Fantuzzi M, Dall’Aglio E, Bonora E, Delsignore R, Passeri M, Reaven GM: Changes in insulin and lipid metabolism in males with asymptomatic hyperuricemia. J Intern Med. 1993, 234: 25-30.CrossRefPubMed
32.
go back to reference Vuorinen-Markkola H, Yki-Järvinen H: Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994, 78: 25-29.PubMed Vuorinen-Markkola H, Yki-Järvinen H: Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994, 78: 25-29.PubMed
33.
go back to reference Facchini F, Ida Chen Y-D, Hollenbeck CB, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration. JAMA. 1991, 266: 3008-3011.CrossRefPubMed Facchini F, Ida Chen Y-D, Hollenbeck CB, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration. JAMA. 1991, 266: 3008-3011.CrossRefPubMed
34.
35.
go back to reference Rathmann W, Funkhouser E, Dyer AR, Roseman JM: Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary artery risk development in young adults. Ann Epidemiol. 1998, 8: 250-261.CrossRefPubMed Rathmann W, Funkhouser E, Dyer AR, Roseman JM: Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary artery risk development in young adults. Ann Epidemiol. 1998, 8: 250-261.CrossRefPubMed
36.
go back to reference Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension. 2003, 41: 1183-1190.CrossRefPubMed Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension. 2003, 41: 1183-1190.CrossRefPubMed
38.
go back to reference Jaques BC, Ginsberg MH: The role of cell surface proteins in platelet stimulation by monosodium urate crystals. Arthritis Rheum. 1982, 25: 508-521.CrossRefPubMed Jaques BC, Ginsberg MH: The role of cell surface proteins in platelet stimulation by monosodium urate crystals. Arthritis Rheum. 1982, 25: 508-521.CrossRefPubMed
39.
go back to reference Chapman PT, Yarwood H, Harrison AA, Stocker CJ, Jamar F, Gundel RH, Peters AM, Haskard DO: Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum. 1997, 40: 955-965.CrossRefPubMed Chapman PT, Yarwood H, Harrison AA, Stocker CJ, Jamar F, Gundel RH, Peters AM, Haskard DO: Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum. 1997, 40: 955-965.CrossRefPubMed
40.
go back to reference Kivity S, Kopel E, Maor E, Abu-BAchar F, Segev S, Sidi Y, Olchovsky D: Association of serum uric acid and cardiovascular disease in healthy adults. Am J Cardiol. 2013, 111: 1146-1151.CrossRefPubMed Kivity S, Kopel E, Maor E, Abu-BAchar F, Segev S, Sidi Y, Olchovsky D: Association of serum uric acid and cardiovascular disease in healthy adults. Am J Cardiol. 2013, 111: 1146-1151.CrossRefPubMed
41.
go back to reference Alderman MH, Cohen H, Madhavan S, Kivlighn S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999, 34: 144-150.CrossRefPubMed Alderman MH, Cohen H, Madhavan S, Kivlighn S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999, 34: 144-150.CrossRefPubMed
42.
go back to reference Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003, 289: 2560-2572.CrossRefPubMed Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003, 289: 2560-2572.CrossRefPubMed
43.
go back to reference Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U: Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005, 165: 1401-1409.CrossRefPubMed Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U: Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005, 165: 1401-1409.CrossRefPubMed
44.
go back to reference Gress TW, Nieto J, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000, 342: 905-912.CrossRefPubMed Gress TW, Nieto J, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000, 342: 905-912.CrossRefPubMed
45.
go back to reference Kim KS, Kim SK, Lee YK, Park SW, Cho YW: Diagnostic value of glycated haemoglobin HbA (1c) for the early detection of diabetes in high-risk subjects. Diabet Med. 2008, 25: 997-1000.CrossRefPubMed Kim KS, Kim SK, Lee YK, Park SW, Cho YW: Diagnostic value of glycated haemoglobin HbA (1c) for the early detection of diabetes in high-risk subjects. Diabet Med. 2008, 25: 997-1000.CrossRefPubMed
46.
go back to reference Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H, Wu P, Teng X, Dong Y, Zhou J, Xu H, Zheng J, Li S, Tao T, Hu Y, Jia Y: Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol. 2010, 47: 231-236.CrossRefPubMed Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H, Wu P, Teng X, Dong Y, Zhou J, Xu H, Zheng J, Li S, Tao T, Hu Y, Jia Y: Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol. 2010, 47: 231-236.CrossRefPubMed
Metadata
Title
Impact of chronic diuretic treatment on glucose homeostasis
Authors
Silvio Buscemi
Antonio Nicolucci
Giuseppe Lucisano
Fabio Galvano
Giuseppe Grosso
Fatima M Massenti
Emanuele Amodio
Alice Bonura
Delia Sprini
Giovam B Rini
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2013
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-5-80

Other articles of this Issue 1/2013

Diabetology & Metabolic Syndrome 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine